Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) related to its merger with Supernus Pharmaceuticals, Inc. Upon closing of the proposed transaction, Indivior shareholders will own approximately 56.5% of the combined company.
Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) related to its merger with Supernus Pharmaceuticals, Inc. Upon closing of the proposed transaction, Indivior shareholders will own approximately 56.5% of the combined company.